info@marketresearchfuture.com   đź“ž  +1 (855) 661-4441(US)   đź“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Pulmonary Atresia Diagnostics Treatment Companies

Pulmonary atresia is a congenital heart defect characterized by the absence or severe narrowing of the pulmonary valve, which is responsible for regulating blood flow from the right side of the heart to the lungs. This condition hinders the normal circulation of oxygenated blood to the lungs, leading to various complications. Early and accurate diagnostics, as well as effective treatment, are crucial in managing pulmonary atresia. 

Pulmonary Atresia Diagnostics and Treatment Market

 


Latest Pulmonary Atresia Diagnostics and Treatment Companies Updates:


Philips: Introduced the Azurion MaxPulse interventional X-ray system featuring enhanced functionalities for complex congenital heart procedures, including those for pulmonary atresia.


Abbott: Expanded the label of its Amplatzer™ Septal Occluder for transcatheter closure of atrial septal defects (ASDs), offering a minimally invasive option for patients with pulmonary atresia who also have an ASD.


Sapiens Transcatheter Solutions: Developed the Harmony Transcatheter Pulmonary Valve system, designed for minimally invasive replacement of malfunctioning pulmonary valves in patients with pulmonary atresia, potentially reducing procedural risks and complications.


Medtronic: Acquired Intersect Medical, gaining access to Intersect's transcatheter aortic valve replacement (TAVR) technology, which could potentially be adapted for future applications in pulmonary valve replacement for patients with pulmonary atresia.


Boston Scientific: Partnered with Children's Hospital Los Angeles to develop and evaluate novel interventions for treating complex congenital heart defects, including pulmonary atresia.


List of Pulmonary Atresia Diagnostics and Treatment Key companies in the market:



  • Kyowa Pharma Chemical Co. Ltd

  • AZAD partners

  • Abbott Laboratories

  • Dickinson and Company

  • Becton

  • C. R. Bard, Inc.

  • B. Braun Melsungen AG

  • Medtronic plc.

  • Teleflex Incorporated

  • JOHNSON & JOHNSON

  • Cook Group Incorporated


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.